- Original
- Published:
Gabapentin in the treatment of migraine and epilepsy comorbid with mood and anxiety disorders
The Journal of Headache and Pain volume 2, pages 83–87 (2001)
Abstract
This open prospective study assessed the use of gabapentin in migraine and epilepsy comorbid with mood and anxiety disorders. After a 4-week baseline period, gabapentin was used as adjunctive treatment in 14 adult patients with both epilepsy and migraine disorders for 3 months. The outcomes were compared with a control group of 14 sex-matched patients with the same disorders, not treated with gabapentin. Both groups were assessed on the Cornell dysthymia rating scale (CDRS), Beck depression inventory (BDI), and Hamilton anxiety scale. A total of 8 (57%) gabapentin-treated patients showed a significant improvement in migraine vs. 3 (21.4%) of the controls. In comparison with controls, the gabapentin-treated group had a significant decrease in CDRS and BDI scores (p<0.05). The results suggest a particular role for gabapentin in the treatment of patients with both epilepsy and migraine comorbid with mood and anxiety disorders.
Author information
Authors and Affiliations
Additional information
Received: 19 January 2001 / Accepted in revised form: 6 July 2001
Rights and permissions
About this article
Cite this article
Martinović, Ž., Ristanović, D. Gabapentin in the treatment of migraine and epilepsy comorbid with mood and anxiety disorders. J Headache Pain 2, 83–87 (2001). https://doi.org/10.1007/s101940170033
Issue Date:
DOI: https://doi.org/10.1007/s101940170033